Literature DB >> 9586889

Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma.

B J Curry1, K Myers, P Hersey.   

Abstract

PURPOSE: The detection of melanoma cells in the circulation by polymerase chain reaction (PCR) assays has been shown by several investigators to correlate with the stage of the disease and possibly with prognosis. PATIENTS AND METHODS: We performed prospective studies on 276 patients with primary melanoma and regional lymph node (LN) metastases to assess the predictive value of PCR detection of tyrosinase and melanoma antigen recognized by T cells-1 (MART-1) in the blood for recurrence of melanoma.
RESULTS: PCR tests for gp 100, Muc-18, and p97 reacted with RNA in blood from healthy subjects and were considered unsuitable for patient monitoring. The tests were most frequently positive in the first 3 months after surgery. There were 47 recurrences in 123 patients who had been followed up for 18 months. Assays within 3 months of surgery predicted recurrence from melanoma in 66% of the latter (tests for tyrosinase alone detected 51% and MART-1 alone 21% of the patients). Hence, 34% of recurrences were not predicted by tests in the early postoperative period. This did not appear to be because of marker-negative melanoma because summation of tests over the first year identified 89% of those with recurrent disease.
CONCLUSION: Positive tests were recorded in 35% of patients who remained disease free, but it is too early to assess whether these represent false-positive results. The false-negative results raise the question of whether the assays will provide a reliable basis for selection of patients for adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586889     DOI: 10.1200/JCO.1998.16.5.1760

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Detection of circulating melanoma cells by immunomagnetic cell sorting.

Authors:  A Benez; A Geiselhart; R Handgretinger; U Schiebel; G Fierlbeck
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 2.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

3.  Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.

Authors:  A L Reid; M Millward; R Pearce; M Lee; M H Frank; A Ireland; L Monshizadeh; T Rai; P Heenan; S Medic; P Kumarasinghe; M Ziman
Journal:  Br J Dermatol       Date:  2012-11-15       Impact factor: 9.302

Review 4.  The changing prognosis of melanoma.

Authors:  A C Buzaid; C M Anderson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

5.  Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?

Authors:  Sandra J Roddiger; Heiner Renneberg; Thomas Martin; Ulf W Tunn; Nikolaos Zamboglou; Ralf Kurek
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-12       Impact factor: 4.553

6.  Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes.

Authors:  A Calogero; H Timmer-Bosscha; H Schraffordt Koops; A T Tiebosch; N H Mulder; G A Hospers
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.

Authors:  T J de Vries; A Fourkour; C J Punt; H Diepstra; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

8.  Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.

Authors:  H Gogas; G Kefala; D Bafaloukos; K Frangia; A Polyzos; D Pectasides; D Tsoutsos; P Panagiotou; J Ioannovich; D Loukopoulos
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

9.  Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients.

Authors:  S Osella-Abate; P Savoia; P Quaglino; M T Fierro; C Leporati; M Ortoncelli; M G Bernengo
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

Review 10.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.